Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer

Exclusion Criteria

• •No myocardial infarction or significant change in anginal pattern within one year or current congestive heart failure (NYHA Class 2 or higher)
• •Patients with a history of hypertension must be well controlled (\< 150/90) on a stable regimen of anti-hypertensive therapy
• •No HIV-positive patients receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with the protocol treatment; (patients with immune deficiency are at an increased risk of lethal infections when treated with marrow-suppressive therapy)
• •No chronic daily treatment with aspirin (\> 325 mg/day) or on non-steroidal antiinflammatory agents known to inhibit platelet function; no treatment with dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix), cilostazol (Pletal), or other antiplatelet agents
• •No clinically significant peripheral neuropathy (grade \>= 2)
• •No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
• •No treatment with therapeutic anticoagulation; prophylactic anticoagulation for central venous access devices is allowed provided requirements of INR \< 1.5 and PTT \< 1.2 x ULN are met; caution should be taken in treating patients with low dose heparin or low molecular weight heparin for DVT prophylaxis as there may be an increased bleeding risk with bevacizumab
• •No current and/or recent (within 1 month) use of a thrombolytic agent; low dose thrombolytic therapy for maintenance of central venous catheter is allowed
• •No clinically significant peripheral arterial disease
• •Non-pregnant and non-nursing; the effect of the combination of bevacizumab, cisplatin, and irinotecan on the fetus and infant is unknown
• •Granulocytes \>= 1,500/μl
• •Platelets \>= 100,000/μl
• •Serum Creatinine =\< ULN
• •Total Bilirubin \< 2.0 mg/dl
• •SGOT \< 2 x ULN
• •INR \< 1.5
• •PTT \< 1.2 x ULN
• •Urine protein (dipstick) \< 1+